INTEL
Sourced

Foot Risk Beyond Diabetes — why FootLab is not a "diabetes app"

Deep dive · OpenFootLab positioning · sourced. The at-risk foot is defined by a mechanism, not a diagnosis. Diabetes is the largest single cause — not the only one, and not a prerequisite.

The thesis

A foot becomes high-risk through one (or more) of three mechanisms. None of them requires diabetes:

  1. Loss of protective sensation (neuropathy) — the person can't feel the injury, so a

blister, seam, pebble, or pressure point becomes a wound before it's noticed.

  1. Poor perfusion (ischemia) — blood can't reach the tissue, so a small wound won't heal

and spreads.

  1. Altered structure / mechanics — deformity, scarring, missing tissue, or a prosthetic

interface concentrates pressure where skin can't tolerate it.

Diabetes is dangerous precisely because it can hit all three at once. But every one of these mechanisms has non-diabetic causes that produce the same at-risk foot and the same need for lifelong monitoring.

Amputation is not mostly a diabetes story — in the people living with it

Two different denominators, both true, and the distinction is the whole point:

  • New amputations (incidence) are dominated by vascular disease — ~82% of amputation

hospital discharges are dysvascular, and that share is rising. Diabetes drives most of it.

  • *People living with limb loss (prevalence)* — the population that needs foot care for

decades — tells a different story. Of the ~1.6 million Americans living with limb loss (projected to rise toward 3.6M+ by 2050), the causes are roughly 54% dysvascular, 45% trauma, <2% cancer. And over two-thirds of the dysvascular cases are diabetic — so a large slice of the dysvascular group is non-diabetic PAD. Net: well over half of people living with limb loss are not there because of diabetes.

Why the gap? Trauma amputees are young and live for 50+ years. They accumulate in the prevalent population. The person who will rely on foot care longest is often not diabetic — he's your car-accident archetype.

The traumatic amputee (your 25-year-old)

  • Trauma-related limb loss skews young and male (mean age ~35; ~83% male in series).
  • Motor-vehicle collisions are the leading cause (~50–58%), then industrial/machinery

crush injuries, then domestic accidents.

  • A partial-foot or below-knee amputation at 25 means 50–60 years of: residual-limb skin

surveillance, prosthetic/orthotic fit checks, scar and pressure management — and watching the remaining foot, which now carries extra load (contralateral overload is a documented new-ulcer risk).

Cancer and congenital — the youngest cohorts

  • Osteosarcoma is the most common bone cancer in kids/young adults (peak age 10–14; ~8

per 100,000 at 10–19). A meaningful fraction still require amputation when limb-salvage isn't possible — a teenager with a lifetime of limb care ahead.

  • Congenital limb deficiency occurs in ~1 in 1,900 U.S. newborns — foot/limb care from

birth, never diabetes-related.

Non-diabetic conditions that create a foot needing lifelong care

ConditionMechanismWhy lifelong foot care
Non-diabetic PAD / critical limb ischemiaIschemiaNon-healing arterial ulcers, gangrene risk; lifelong vascular + wound surveillance
Traumatic (partial) amputationStructure + often nerveResidual limb + contralateral overload for decades
Chemotherapy-induced peripheral neuropathy (CIPN)Neuropathy~52% of chemo patients affected; persists in a large share (~58% of breast-cancer survivors at ~5.6 yrs) → insensate feet in millions of survivors
Charcot-Marie-Tooth & hereditary neuropathiesNeuropathy + deformityMost common inherited neuropathy (~1/2,500); high-arch/clawtoe deformity, insensate
Spinal cord injuryNeuropathy (insensate)Pressure injury prevalence 23–39%; 37% rehospitalized for a pressure ulcer by year 20
Spina bifida / myelomeningoceleNeuropathy (congenital)Lifelong multi-system; insensate feet; foot pressure ulcers ~8.8%
Rheumatoid & inflammatory arthritisStructure (deformity)Foot involvement in 30–90%; foot ulcers in ~10%
Leprosy (Hansen's disease)Neuropathy (insensate)The leading cause of Charcot/insensate foot worldwide in endemic areas
Chronic kidney disease / dialysisIschemia + neuropathyIndependent driver of Charcot and non-healing wounds
Stroke / hemiplegiaStructure (altered gait/load)Spastic foot, altered pressure, reduced self-inspection
Congenital insensitivity to pain, syringomyelia, syphilis, alcoholic neuropathy, B12 deficiencyNeuropathyAll documented non-diabetic causes of the neuropathic/Charcot foot
Venous insufficiency / lymphedemaTissue integrityChronic leg/foot ulceration, lifelong skin care

The through-line: once at risk, always monitoring

Two facts unify the whole list:

  1. An insensate, ischemic, or deformed foot doesn't heal itself and doesn't warn you — the

patient needs an external early-warning loop, exactly what a daily foot check provides.

  1. *Any amputation makes the other foot a high-risk foot.* Every amputee — traumatic,

oncologic, congenital, or diabetic — has a residual limb and a contralateral foot to watch for the rest of their life.

What this means for OpenFootLab

  • Reframe the addressable population. FootLab is not a diabetes product with a foot feature;

it's a foot-at-risk platform. Diabetes is the biggest single wedge, but the same insensate/ischemic/deformed-foot problem covers trauma amputees, CIPN cancer survivors, CMT, RA, SCI, spina bifida, leprosy, PAD, and every amputee's remaining foot.

  • The product already generalizes. The observation vocabulary (redness, swelling, wound,

drainage, discoloration, pressure/friction) and the escalation logic are condition-agnostic. Only the context changes — and the harness already loads that from Baseline/ / patient_baseline.json as free text, so a non-diabetic profile ("post-traumatic right partial foot amputation, 2026 MVA") drops in without code changes.

  • The Foot Passport is the right container for all of them. A lifelong, portable, owner-owned

record is more valuable for a 25-year-old trauma amputee with 60 years ahead than for anyone.

  • Positioning line: *"If your foot can't feel it, can't heal it, or can't take the pressure —

FootLab watches it. You don't need to be diabetic."*


Sources

  • Ziegler-Graham et al., Estimating the Prevalence of Limb Loss in the United States: 2005 to 2050, Arch Phys Med Rehabil (2008) — https://pubmed.ncbi.nlm.nih.gov/18295618/
  • Estimating Recent US Limb Loss Prevalence and Updating Future Projections (2024) — https://pmc.ncbi.nlm.nih.gov/articles/PMC11734033/
  • Lower Limb Amputations: Epidemiology and Assessment, AAPM&R KnowledgeNow — https://now.aapmr.org/lower-limb-amputations-epidemiology-and-assessment/
  • Epidemiology of Post-Traumatic Limb Amputation: NTDB Analysis — https://journals.sagepub.com/doi/10.1177/000313481007601120
  • PAD and the Diabetic Foot Syndrome: Neuropathy Makes the Difference — https://pmc.ncbi.nlm.nih.gov/articles/PMC11012336/
  • Global prevalence of chemotherapy-induced peripheral neuropathy: systematic review & meta-analysis — https://pmc.ncbi.nlm.nih.gov/articles/PMC12977667/
  • Long-term CIPN among breast cancer survivors — https://pmc.ncbi.nlm.nih.gov/articles/PMC5509538/
  • Charcot foot pathophysiology overview (non-diabetic etiologies) — https://pmc.ncbi.nlm.nih.gov/articles/PMC3733015/
  • Lepromatous Leprosy and Charcot Neuroarthropathy of Insensate Feet — https://pmc.ncbi.nlm.nih.gov/articles/PMC11214381/
  • Prevention of Pressure Ulcers Among People With Spinal Cord Injury — https://www.sciencedirect.com/science/article/abs/pii/S1934148214015524
  • Foot pressure ulcers in ambulatory pediatric spina bifida — https://pubmed.ncbi.nlm.nih.gov/31480906/
  • Prevalence of foot ulceration in rheumatoid arthritis — https://pubmed.ncbi.nlm.nih.gov/18240257/
  • Charcot-Marie-Tooth Hereditary Neuropathy Overview, GeneReviews — https://www.ncbi.nlm.nih.gov/books/NBK1358/
  • Cancer-Specific Survival after Limb Salvage vs Amputation in Osteosarcoma — https://pmc.ncbi.nlm.nih.gov/articles/PMC10118882/

Not medical advice. Prevalence figures are cited from the linked literature and vary by population and method.